SBI Securities
DMAC icon

SBI Securities’s DiaMedica Therapeutics DMAC Stock Holding History

SBI Securities’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$827 Buy
+100
New +$699 ﹤0.01% 2925

Other funds holding DMAC

Members Wealth
Members Wealth Media, Pennsylvania $200M AUM 9.84% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GK Wealth Management
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities's DMAC Position: Q3 2026 in Review

SBI Securities opened a new position in DiaMedica Therapeutics (DMAC) in Q3 2026: 100 shares worth $827. The stake represents ﹤0.01% of the portfolio and ranks #2925 among its holdings.

9 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • SBI Securities held 100 shares of DiaMedica Therapeutics worth $827 as of Q3 2026.
  • DiaMedica Therapeutics was a new SBI Securities position in Q3 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2925 holding.
  • 9 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.